Ultragenyx Pharmaceutical, Inc. (RARE)
25.16
+0.59
(+2.40%)
USD |
NASDAQ |
Apr 15, 16:00
25.16
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Research and Development Expense (Annual) : 723.00M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Corcept Therapeutics, Inc. | 254.91M |
| Catalyst Pharmaceuticals, Inc. | 12.71M |
| BioMarin Pharmaceutical, Inc. | 700.97M |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Xencor, Inc. | 239.43M |